

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/755,086	01/09/2004	David S. Lawrence	96700/860	8599	
7	7590 07/05/2006		EXAMINER		
Alan D. Miller AMSTER, ROTHSTEIN & EBENSTEIN LLP			PETERSEN, CLARK D		
90 Park Avenu				PAPER NUMBER	
New York, NY	Y 10016		1655		
			DATE MAILED: 07/05/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/755,086	LAWRENCE, DAV	/ID S.			
Office Action Summary	Examiner	Art Unit				
	Clark D. Petersen	1655	,			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status		•				
1) Responsive to communication(s) filed on 09	9 January 2004.					
·— ·	his action is non-final.					
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1,3,4,49-123,127-131,133 and 13-	$\underline{4}$ is/are pending in the applic	ation.				
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1, 3, 4, 49-123, 127-131, 133 and 134</u> are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> </ol>	Paper No	(s)/Mail Date				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB Paper No(s)/Mail Date		Informal Patent Application (PT	O-152)			

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 3 and 4, drawn to a method of identifying a compound that inhibits a kinase by providing a fluorogenic substrate peptide for the kinase and measuring changes in fluorescence intensity with or without the presence of a given compound, classified in class 435, subclass 15, for example.
- II. Claims 49-123, 127-131, and 133-134, drawn to a substrate or chemical compound that can be photoactivated and is a fluorogenic substrate for kinases, classified in class 424, subclass 9.6, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the product of Invention II can be used in a materially different process. The product of Invention II registers kinase activity. Discovery of compounds that influence kinase activity is not the only

potential application for information gathered through use of a fluorogenic substrate; for example, localization of kinase activity within a cell, or determination of pathophysiological states within an organism by measuring inappropriate kinase activation might be determined by measuring kinase activity using this substrate.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, and because these inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species:

- A. The various types of kinase to be tested by a substrate (see, e.g., claims 68-70).
- B. The various molecules comprising the substrate (see, e.g., claim 71).
- C. The various fluorophores (see, e.g. claims 78-80).
- D. The various linkers (see, e.g., claims 82-85).
- E. The various compounds set forth in table 3 (see, e.g., claim 88).

The species are independent or distinct because various kinases have different substrate requirements, and represent different fields of study. Different molecules such as lipids and nucleic acids are involved in enzymatic assays directed toward different goals. Different fluorophores are chemically distinct and are used for different

Art Unit: 1655

conditions. Different linkers comprise different chemical structures with different chemical properties. For all the reasons above, searching the various groups of species in their entireties would involve extensive, non-overlapping searches and therefore presents an undue search burden on the examiner. Therefore it is reasonable for the examiner to require elections of species.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for a kinase for which a substrate is specific, i.e., the combination of three isoforms of PKC of claim 69, **OR** a single kinase from among those disclosed in claim 70. Applicant is also required to elect a single species of molecule comprised by a substrate, i.e., one of a nucleic acid, a lipid, or a carbohydrate. Applicant is also required to elect a single disclosed combination of one linker, one substrate, and one fluorophore for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 56, 68, 70, 71, 77, and 81 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after

Application/Control Number: 10/755,086 Page 5

Art Unit: 1655

the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Art Unit: 1655

## Notice of Possible Rejoinder

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Application/Control Number: 10/755,086

Art Unit: 1655

## Conclusion

Page 7

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Clark D. Petersen whose telephone number is (571)272-5358. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571)272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CDP 6/26/2006

> dávid m. naff Prímary examiner,

ART UNIT 128 165/